Up close and personal with ASX tech and Biotech - *
ST0CKH#ADImugene (ASX:IMU) is a clinical stage immuno-oncology company working to develop a range of new treatments that seek to activate the immune system of cancer patients to identify and eradicate tumours.
CEO and managing director Leslie Chong says IMU products work to unleash a person’s immune system and hopefully lead to a cancer cure along with viruses that are also helpful in attacking tumours.
“We are trying to alleviate the scourge of cancer and have a product we call Azer-cel, which is allogeneic CAR T that go against certain type of blood cancers and maybe provide a long-term cure for lymphoma so that is our priority product,” she says.
Here is Chong to explain more:
Why IMU is a multi multi bagger, page-23455
-
- There are more pages in this discussion • 2,606 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
